Eradication of Prostate Cancer Using F-989

The purpose of this study is to confirm the findings of an early study with prostate cancer and to expand our knowledge of treating prostate cancer using F-989.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostate Cancer Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

40 year–75 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinical diagnosis of prostate cancer
Referred to the study by their treating physician

Exclusion criteria

Any type of treatment before starting study

Treatment and study plan

Acetogenins

Dietary Supplement

Primary outcomes

Gleason Score

Time frame: 1 year

A Gleason Score is obtained from the results of a transrectal needle biopsy of the prostate.

Secondary outcomes

Prostate Specific Antigens (PSA)

Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Optimal Health Research

Other

Registry information

Official study title

Phase II Eradication of Prostate Cancer Using F-989

Important dates

Study start: 2013
Primary completion: 2015
Study completion: 2015
First posted: Nov 20, 2013
Registry last updated: Sep 20, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed